Resverlogix grants Shenzhen Hepalink rights to RVX208 in some Asian territories; right of first refusal in US
Resverlogix Corp. has licensed Shenzhen Hepalink Pharmaceutical Co. Ltd. rights to develop its lead cardiovascular compound RVX208 in China, Hong Kong, Taiwan, and Macau.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.